INTRODUCTION AND OBJECTIVES:
We aim to determine the effect of anastrazole on hormonal and seminal parameters in hypoandrogenic subfertile men. We also aim to assess whether seminal parameter changes are correlated to the magnitude of increase in testosterone to estrogen ratio in men responding to treatment.
METHODS: A retrospective review was performed of all hypogonadal subfertile men attending a male infertility clinic and treated with anastrazole. Hormone analysis before treatment, 2 weeks after starting treatment and 4 months after were performed. Hormone analysis included measurements of total testosterone, estradiol, sex-hormone binding globulin, albumin, FSH and LH, and bioavailable testosterone was calculated. Semen analyses before treatment and 4 months after treatment were recorded. Total motile sperm count was calculated from the semen analysis. For statistical analysis, variables are presented as median interquartile range or mean AE standard error. A matched pairs analysis estimated significance of change in laboratory values and semen analyses with treatment. A sub-group analysis was performed of men with baseline oligozoospermia. In this group, we used linear regression to identify correlations between changes in hormone concentrations and increase in semen parameters.
RESULTS: The study group consisted of 86 subfertile hypoandrogenic men with low testosterone to estradiol ratio (n¼78) or a prior aversive reaction to clomiphene citrate (n¼8). 95.3% of patients had an increased serum testosterone and decreased serum estradiol following treatment with anastrozole. Sperm concentration and total motile counts improved in 18 out of 21 subfertile hypoandrogenic oligozoospermic men treated with anastrozole. In these men, the magnitude of total motile count increase was significantly correlated with the change in the testosterone to estradiol ratio. None of the men with azoospermia or cryptozoospermia experienced an improvement in sperm in the ejaculate and microTESE recovery rates were 72.7% in these men.
CONCLUSIONS: Approximately 95% of men with hypoandrogenism responded with improved endocrine parameters, and a subset of oligozoospermic men (approximately 25% of all patients) displayed significantly improved sperm parameters. In that subset, increase in sperm parameters was correlated with the change in the testosterone to estradiol ratio, which argues for a physiological effect of treatment. There are currently no oral treatments of male infertility approved for use by the Food and Drug Administration. The selective estrogen receptor modulator Clomiphene is the most commonly prescribed such agent, however its usage is only described in case series. We sought to characterize the demographics and usage patterns of Clomiphene for male infertility across the United States.
Source of Funding: None
METHODS: This is a retrospective cohort study of individuals in the Truven Health MarketScanâ claims database from 2001 to 2009. This US database provides information of insurance claims filed for the care of privately insured individuals with employment-based insurance. While the number of enrollees varies between years, recent years contained up to 30 million people. Pharmacy claims were used to identify the usage patterns of Clomiphene among male enrollees. Associated diagnoses and treatments were identified by utilizing International Classification of Diseases, 9th edition (ICD-9) and Current Procedural Terminology (CPT) codes. Rates of side effects previously reported for Clomiphene were compared 6 months before and 6 months after medication usage.
RESULTS: 3,922 men took Clomiphene and represented the primary study cohort, with a mean age of 35 years. Usage varied between 0.3% to 0.8%, with the highest prevalence among men 30-39 years old. No trend of usage was noted during the study period. Associated diagnoses of Clomiphene users included male infertility (59%), testicular hypofunction (32%), erectile dysfunction (8.6%), and low libido (0.6%). Infertility evaluation with semen analysis was performed in 55% of men. Testing for testosterone, LH, and FSH was done in 38%, 31%, and 35%. The median time of use was 2.4 months, with 73% of men stopping within 6 months, 17% stopping within the first year, and 3% continuing for more than 2 years. No increased risk of reported Clomiphene side effects (thrombotic events, vision problems, gynecomastia, mental disorders, liver disease, nausea, or skin problems) were apparent in men taking the medication.
CONCLUSIONS: The current report is the first to characterize the demographics and national usage patterns of Clomiphene, the most commonly prescribed oral agent for male infertility. Knowledge of adjuvant testing and prescribing practices for Clomiphene may inform and improve patient care. No increased risk of reported side effects was detected. Additional studies are needed to further understand indications, efficacy, and safety of Clomiphene use in men. 
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INTRODUCTION AND OBJECTIVES:
Multiple studies have demonstrated a higher intrauterine insemination (IUI) pregnancy success in men with >4% normal morphology compared to men with 4% normal sperm morphology; other studies have not demonstrated this relationship. We performed a systematic review and meta-analysis to assess the effect of abnormal sperm morphology on pregnancy success for couples undergoing IUI.
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